SAN DIEGO--(BUSINESS WIRE)--Youngevity Essential Life Sciences, a wholly owned subsidiary of Youngevity International Inc., (OTCQX: YGYI) (www.YGYI.com), announced that is has filed official Comments in response to the FDA’s Proposed Rule, “Infant Formula: The Addition of Minimum and Maximum Levels of Selenium to Infant Formula and Related Labeling Requirements.”
The Proposed Rule would require inclusion of selenium in infant formula, which has now been confirmed by the FDA to be “an essential trace element for humans” adding that selenium deficiencies “may be of greatest concern in infants and children” especially to those that are entirely fed through formula.
In support of the Proposed Rule, Youngevity and its distributors filed official Comments reiterating selenium’s integral role as part of a healthy diet. Youngevity’s Comment also relied on an evaluation by noted researcher, chemist, and scholar Dr. G.N. Schrauzer, Ph.D. who also serves on Youngevity’s Scientific Advisory Board. Citing Dr. Schrauzer’s expert opinion, Youngevity recommended that the FDA require the use of an organic form of selenium, selenomethionine, which provides greater health benefits to humans than does the mineral’s inorganic form, sodium selenate.
Youngevity has long been a strong advocate of providing the public with important, truthful information about such health benefits and this is only the latest measure taken in support of health derived from supplementation. Youngevity has already successfully petitioned the FDA to allow such claims concerning the consumption of certain omega-3 fatty acids to reduce the risk of coronary heart disease and of the consumption of selenium to reduce the risk of bladder cancer in women as well as prostate and thyroid cancers.
Youngevity CEO, Steve Wallach, stated, “My father, and Youngevity founder, Dr. Joel Wallach, has been at the forefront of Selenium research for nearly 40 years and the Proposed Rule would only amplify the importance of mineral supplementation, especially to children who rely on infant formula as their only nutrient source.”
The FDA will continue to accept comments on its Proposed Rule until July 1, 2013. Visit www.youngevity.com/ for a copy of the Youngevity Comment and supporting documents.
About Youngevity® Essential Life Sciences
Youngevity Essential Life Sciences (www.youngevity.com), headquartered in San Diego, CA, is a nutrition and lifestyle-related services company dedicated to promoting vibrant health and flourishing economics. Founded in 1997 by Drs. Joel Wallach, DVM, ND, and Ma Lan, MD, as AL Global, Inc., the company adopted the name Youngevity in 2006. Youngevity is the only direct selling company to have a qualified FDA Health Claim. Dr. Wallach’s work has been published in more than 70 peer-reviewed and referenced scientific journals and books.
About Youngevity International Inc.
Youngevity International Inc., (OTCQX: YGYI) (www.YGYI.com) is a fast-growing, innovative, multi-dimensional company that offers a wide range of consumer products and services, primarily through person-to-person selling relationships that comprise a "network of networks." The company also is a vertically-integrated producer of the finest coffees for the commercial, retail and direct sales channels. Youngevity International Inc. was formed after the merger of Youngevity Essential Life Sciences (www.youngevity.com) and Javalution Coffee Company in the summer of 2011.
Safe Harbor Statement
This release includes forward-looking statements on our current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. . The forward-looking statements contained in this press release include statements regarding the Company’s future growth. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.